medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2008, Number 2

<< Back Next >>

Ann Hepatol 2008; 7 (2)

Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients

Otegbayo JA, Taiwo BO, Akingbola TS, Odaibo GN, Adedapo KS, Penugonda S, Adewole IF, Olaleye DO, Murphy R, Kanki P

Language: English
References: 27
Page: 152-156
PDF size: 128.04 Kb.


Text Extraction

Introduction: The clinical and public health implications of the convergence of the human immunodeficiency virus (HIV) epidemic and chronic viral hepatitis in sub-Saharan Africa are poorly understood. This study was designed to determine the seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV), and the impact of co-infection on baseline serum alanine transaminase (ALT), CD4+ T lymphocyte (CD4) count, and plasma HIV-RNA (viral load) in a cohort of HIV-infected Nigerians. Methods: A retrospective study was conducted, on eligible treatment-naive patients who presented between August 2004 and February 2007 to the University College Hospital (UCH), Ibadan, Nigeria. Demographic data and pre-treatment laboratory results (hepatitis B surface antigen (HBsAg), HCV antibodies (anti-HCV), ALT, CD4 count and viral load) were retrieved from the medical records. Fisher’s exact, two sample t-tests, and the Wilcoxon rank sum tests were used to compare groups. A logistic regression model was fitted to explore characteristics associated with co-infection status. Results: A total of 1779 HIV-infected patients (male: female ratio, 1:2) met inclusion criteria. HBsAg was present in 11.9%, anti-HCV in 4.8% and both markers in 1%. HBsAg was more common among males than females (15.4% vs 10.1%, respectively p = 0.001) while anti-HCV was detected in a similar proportion of males and females (5.3% versus 4.6%, respectively p = 0.559). HIV-infected patients with anti-HCV alone had a lower mean baseline CD4 count compared to those without anti-HCV or HBsAg (197 cells/mm3 vs 247 cells/mm3, respectively p = 0.008). Serum ALT was higher among patients with HBsAg compared to those without HBsAg or anti-HCV (43 International Units (IU) vs. 39 IU, respectively p = 0.015). Male gender was associated with HBV co-infection on logistic regression (OR1.786; 95% CI, 1.306-2.443; p › 0.005). Conclusion: More HIV-infected females than males presented for care in this cohort. We identified a relatively high prevalence of HBV and HCV co-infection in general, and a higher rate of HBV co-infection among males than females. Pre-treatment CD4 count was significantly lower among those with HCV co-infection, while ALT was slightly higher among those with HBV co-infection. Triple infection with HIV, HBV and HCV was present in a small but significant proportion of patients. These findings underscore the importance of testing for HBV and HCV in all HIV-infected persons in our setting.


REFERENCES

  1. WHO (2003). World health report: 2003: shaping the future. Geneva. ISBN 92 4 156243 9.

  2. Modi AA, Feld JJ. Viral hepatitis and HIV in Africa. AIDS Rev 2007; 9(1): 25-39.

  3. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16.

  4. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, Thomas DL. Multicenter AIDS Cohort Study. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360:1921-1926.

  5. García-Samaniegorez Rodríguez M, Berenguer J, Rodríguez-Rosado R, Carbó J, Asensi V, Soriano V. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001 ; 96: 179-183.

  6. Mariné-Barjoan E, Saint-Paul MC, Pradier C, et al. Impact of antiretroviral treatment on progression of hepatic fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 2004; 18(16): 2163-70.

  7. Aceti A, Pasquazzi C, Zechini B, et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002; 29(1): 41-8.

  8. Thomas DL. Growing importance of liver disease in HIV-infected persons. Hepatology 2006; 43: S221-S229.

  9. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007; 356: 1445-1454.

  10. Braga P, Cardoso MR, Segurado AC. Gender differences in survival in an HIV/AIDS cohort from Sao Paulo, Brazil. AIDS Patient Care STDS 2007; 21: 321-328.

  11. Hosegood V, Jaffar S, Bätzing-Feigenbaum J, Herbst K, Newell ML. Continued very high prevalence of HIV infection in rural KwaZulu-Natal, South Africa: a population-based longitudinal study. AIDS 2007; 2111: 1467-1472.

  12. Seeley J, Grellier R, Barnett T. Gender and HIV/AIDS impact mitigation in sub-Saharan Africa-recognizing the constraints. SAHARA J 2004; 1: 87-98.

  13. Ola SO, Ladipo MM, Otegbayo JA, Odaibo GN, Bamgboye EA, Nwaorgu OG, Shokunbi SW, Olaleye OD. Demographic factors in HIV infected patients seen at UCH, Ibadan, Nigeria. Afr J Med Med Sci 2005; 34: 297-301.

  14. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166(15): 1632-41.

  15. Sirisena ND, Njoku MO, Idoko JA, et al. Carriage rate of hepatitis-B surface antigen (HBsAg) in an urban community in Jos Plateau State, Nigeria. Niger Postgrad Med J 2002; 9: 7-10.

  16. Uneke CJ, Ogbu O, Inyama PU, Anyanwu GI, Njoku MO, Idoko JH. Prevalence of hepatitis-B surface antigen among blood donors and human immunodeficiency virus-infected patients in Jos, Nigeria. Mem Inst Oswaldo Cruz 2005; 100: 13-16.

  17. Davis L, Weber D, Lemon S. Horizontal transmission of HBV. Lancet 1989: 889-93.

  18. Drew JS, London WT, Lustbader ED, et al. Cross-reactivity between HBsAg and a male-associated antigen. Birth Defects 1978; 15: 91.

  19. Zhou J, Dore GJ, Zhang F, et al. Hepatitis B and C virus coinfection in The TREAT Asia HIV Observational Database. J Gastroenterol Hepatol 2007; 22(9): 1510-8.

  20. Agwale SM, Tanimoto L, Womack C, et al. Prevalence of HCV coinfection in HIV-infected individuals in Nigeria and characterization of HCV genotypes. J Clin Virol 2004; 31Suppl 1: S3-6.

  21. Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006; 35: 14-20.

  22. Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001; 26: 340-344.

  23. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356: 1800-5.

  24. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 2004; 39: 1507-13.

  25. Hershow RC, O’Driscoll PT, Handelsman E, et al. Hepatitis C virus coinfection and HIV load, CD4+ cell percentage, and clinical progression to AIDS or death among HIV-infected women: Women and Infants Transmission Study. Clin Infect Dis 2005; 40: 859-6.

  26. Rockstroh JK, Mocroft A, Soriano V, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192(6): 992-1002.

  27. Stebbing J, Waters L, Mandalia S, et al. Hepatitis C virus infection in HIV type 1-infected individuals does not accelerate a decrease in the CD4+ cell count but does increase the likelihood of AIDS-defining events. Clin Infect Dis 2005; 41(6): 906-1.




2020     |     www.medigraphic.com